Gene Delivery Technologies Market Trends and Forecast Report 2024-2033 | By Types, Applications, Regions And Players

The Gene Delivery Technologies Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Gene Delivery Technologies Market:

https://www.thebusinessresearchcompany.com/report/gene-delivery-technologies-global-market-report

According to The Business Research Company’s Gene Delivery Technologies Global Market Report 2024, The gene delivery technologies market size has grown rapidly in recent years. It will grow from $3.57 billion in 2023 to $4.11 billion in 2024 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to enhanced understanding of genetic diseases, advancements in cell therapy, evolution of nanotechnology, growth of gene therapy trials, research funding increase.

The gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $6.96 billion in 2028 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to precision medicine development, regulatory framework enhancements, proliferation of gene therapy, expansion of non-viral delivery systems. Major trends in the forecast period include application in rare diseases, rise in clinical trials, targeted drug delivery, expansion of cell therapy, development of gene editing tools.

The increasing number of cell and gene therapies is expected to propel the growth of the gene delivery technologies market going forward. Cell and gene therapies refer to medical treatments that aim to cure or alleviate diseases by altering a patient’s body’s genetic and cellular makeup. The increasing number of cell and gene therapies is mainly driven by advancements in gene editing technologies, playing a critical role in developing and commercializing cell and gene therapies. For instance, in October 2022, according to an article published by Economist Impact, a UK-based corporation empowering businesses, governments, and foundations to catalyze change and enable progress, in mid-2021 around 2,600 clinical trials for CGTs were underway. Companies have conducted over half of it since 2015, and these have increased as per their research demand in multiple fields. Researchers estimate that by 2031, the United States will have 100 approved CGTs. Additionally, between 2022 and 2031, the FDA is expected to approve 8 or 9 CGTs per year on average. Therefore, increasing cell and gene therapies drives the gene delivery technologies market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10706&type=smp

The gene delivery technologies market covered in this report is segmented –

1) By Mode: Biological, Chemical, Physical

2) By Method: Ex Vivo, In Vivo, In Vitro

3) By Application: Gene Therapy, Cell Therapy, Vaccines, Research

Technological advancement has emerged as a key trend gaining popularity in the gene delivery technologies market. Major market players are concentrating their efforts on creating technologically advanced products to strengthen their position in the market. For instance, in February 2023, Aera Therapeutics, a US-based biotechnology company, launched Aera’s Platform delivery technology to unlock the potential of genetic medicines. Aera’s PNP technology allows for the precise targeting of RNA molecules that are involved in disease processes. This technology allows for the targeted editing of genes in a patient’s cells, offering the potential for personalized gene therapies.

The gene delivery technologies market report table of contents includes: